[Comment] Rifasutenizol-based triple therapy for Helicobacter pylori infection

Helicobacter pylori infection is the primary cause of gastroduodenal diseases and current guidelines recommend eradication therapy for all patients regardless of symptom presentation.1,2 Over the past 30 years, promising advances in H pylori treatment have been achieved through continuous improvements in acid suppressants (eg, potassium-competitive acid blockers [P-CABs] and proton pump inhibitors) and optimisation of existing antibiotic combination regimens (eg, bismuth subcitrate potassium, metronidazole, plus tetracycline; and omeprazole, amoxicillin, plus rifabutin).